Georgetown Lombardi Visiting Professor and Grand Rounds Lecture Series Featuring Daniel Hertz, PharmD, PhD
“Efforts Towards Universal Implementation of DYPD Testing”
Daniel Hertz, PharmD, PhD
University of Michigan
Sponsor: Dr. Sandra Swain
Dr. Hertz is an assistant professor in the Department of Clinical Pharmacy at the University of Michigan College of Pharmacy. Dr. Hertz received his PharmD from Rutgers University and PhD from University of North Carolina for his dissertation research on pharmacogenetic predictors of taxane-induced neuropathy. Dr. Hertz’s current research is interested in developing tools for individualizing treatment in patients with cancer and translating them into clinical practice. He has particular interests in optimal dosing of paclitaxel and using DPYD genotype to optimize fluoropyrimidine chemotherapy. Dr. Hertz has several other ongoing projects to discover and translate genetic variants that affect cancer treatment outcomes, in collaborations with medical oncologists at the University of Michigan Rogel Cancer Center and within SWOG.